0.00Open0.00Pre Close0 Volume0 Open Interest5.00Strike Price0.00Turnover0.00%IV10.39%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier12DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma1.14Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Nuvectis Pharma Stock Discussion
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2024 AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics
Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA for NXP800 for the Treatment of ARID1a-deficient Ovarian, Fallopian Tube, and Primary Peritoneal Cancers
Nuvectis Pharma (NASDAQ: NVCT) has announced that its drug NXP800 has received Orphan Drug Designation from the FDA for treating ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers. This designation is significant as ovarian cancer typically exceeds the 200,000 patient thr...
- support $10 resistance $12
$RCM Technologies (RCMT.US)$
- support $18.45 resistance $20
$Livent (LTHM.US)$
- Support $27 resistance $30
$Innoviz Technologies (INVZ.US)$
- support $4.75 Resistance $5.5
$Forge Global (FRGE.US)$
- support $32 resistance $35
- Support $14 resistance $16.5
$Nuvectis Pharma (NVCT.US)$
- support $9.6 resistance $11
$Mirum Pharmaceuticals (MIRM.US)$
- Support $25 and resistance $30
$Peabody Energy (BTU.US)$
- support $31 resistance $35
$NextDecade (NEXT.US)$
- Support $6.65 resistance $7.5
$Nuvectis Pharma (NVCT.US)$ - support $9.6 resistance $11
$Mirum Pharmaceuticals (MIRM.US)$ - Support $25 and resistance $30
$Biofrontera (BFRI.US)$ - support $4 resistance $5
$Lixte Biotechnology (LIXT.US)$ - Support $1.6 resistance $2
No comment yet